SEASON ONE · EPISODE 02 OUT NOW

The medicines that changed us—and the stories behind them.

NEW EPISODE Amgen: How a Biotech Startup Became Big Pharma
01INSULIN
02rDNA
03SILDENAFIL
THE GOOD PHARMA IDEA

Pharma and biotech have an outsized impact—and receive undersized attention.

Good Pharma is a podcast, created by Deeya Kotecha, exploring the business, science, and human stories behind medicine.

Deeya trained in medicine at Cambridge and worked as a doctor before moving into public markets and venture capital. She writes about biotechnology, the history of drugs, and the business of medicine. More about Deeya →

Behind the medicines are daring founders, accidental discoveries, difficult tradeoffs, and decades-long bets. Good Pharma follows those stories to understand how treatments are discovered, developed, and brought to the people who need them.

“The history of medicine is a history of people deciding what progress should mean.”

GOOD PHARMA · EDITORIAL NOTE
THE SHELF

Explore every episode

THE METHOD
01

Start with the record

We spend hundreds of hours reading books, papers, primary sources, and archives—then speaking with the people who were there.

02

Follow the incentives

The business story matters because incentives determine which ideas get funded, which medicines get developed, how they reach patients, and who can afford them.

03

Keep the human scale

Science becomes real in people’s lives. We keep patients, clinicians, researchers, and families at the center of every story.

NOTES FROM THE RESEARCH DESK

Never miss a story.

THE STORY

How a Biotech Startup Became Big Pharma

OVERVIEW

Deeya and Rohan trace Amgen’s history, from its founding and the discovery of erythropoietin to the blockbuster drugs and acquisitions that transformed the business. We explore Epogen and Neupogen, the consequential Johnson & Johnson partnership, and the Immunex acquisition that brought Enbrel into the company.

Along the way, we examine EPO’s safety reckoning, the science behind newer medicines like Repatha, and how drug pricing, insurance and pharmacy benefit managers (PBM) shape what patients pay. This is a story about biotechnology, entrepreneurship and the challenge of turning great science into a lasting business.

02Season one
1:05:15Episode runtime
12Chapters

CHAPTERS

  1. Introduction
  2. The Origins of EPO
  3. Founding Amgen
  4. The EPO Breakthrough
  5. The Deals That Saved Amgen
  6. Building the Blockbuster Business
  7. The Immunex Acquisition
  8. The EPO Reckoning
  9. The Next Generation of Medicines
  10. The Business of Drug Pricing
  11. Amgen Today
  12. Lessons from Amgen

This space is reserved for sources, reading notes, timelines, and corrections published alongside the episode.

The transcript will be added here when available.

NEXT ON THE SHELF

Continue the story.

GOOD PHARMA EPISODE 01 ELILILLY STORIES BEHIND MEDICINE Eli Lilly, Part 1 →